Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients.In the studies, known as LIBERTY AD SOLO 1 and SOLO 2, treatment with dupilumab as monotherapy significantly improved measures of overall disease severity, skin clearing, itching, quality of life, and mental health.
Link:
www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-positive-dupilumab-topline-results-from-two-phase-3-trials-in-inadequately-controlled-moderate-to-severe-atopic-dermatitis-patients-300244487.html
Link:
www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-positive-dupilumab-topline-results-from-two-phase-3-trials-in-inadequately-controlled-moderate-to-severe-atopic-dermatitis-patients-300244487.html
No comments:
Post a Comment